Author Archives: Joana Carvalho

Study Urges Careful Analysis of MAIHA Patients to Optimize Treatment

The profile of patients with mixed autoimmune hemolytic anemia (MAIHA) must be carefully analyzed to facilitate diagnosis and disease management, a study says. The findings of the study, “Immunohematological and clinical characterizations of mixed autoimmune hemolytic anemia,” were published in the Asian Journal of Transfusion Science.

Apellis’ APL-2 Receives FDA’s Orphan Drug Designation for AIHA

APL-2, Apellis Pharmaceuticals‘ investigational compound for the treatment of autoimmune hemolytic anemia (AIHA) and other complement system diseases, has received the designation of orphan drug from the U.S. Food and Drug Administration (FDA) for the treatment of AIHA. “This orphan drug designation represents an important recognition by…